Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.

Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet WS, Lacey DL, Goldberg AL, Han HQ.

Cell. 2010 Aug 20;142(4):531-43. doi: 10.1016/j.cell.2010.07.011.

2.

Loss of skeletal muscle in cancer: biochemical mechanisms.

Tisdale MJ.

Front Biosci. 2001 Feb 1;6:D164-74. Review.

PMID:
11171557
3.

Pathophysiology of peripheral muscle wasting in cardiac cachexia.

Filippatos GS, Anker SD, Kremastinos DT.

Curr Opin Clin Nutr Metab Care. 2005 May;8(3):249-54. Review.

PMID:
15809526
4.

Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia.

Melstrom LG, Melstrom KA Jr, Ding XZ, Adrian TE.

Histol Histopathol. 2007 Jul;22(7):805-14. Review.

PMID:
17455154
5.

[Cachexia in chronic cardiac disease. Ancient syndrome new idea?].

Jastrezebska-Maj E, Mizia-Stec K, Kasprzyk M, Straczkowski M, Al-Jeabory M, Jastrzebska-Okoń K, Gasior Z.

Przegl Lek. 2006;63(3):151-4. Review. Polish.

PMID:
16967702
6.

Waste management - cytokines, growth factors and cachexia.

Saini A, Al-Shanti N, Stewart CE.

Cytokine Growth Factor Rev. 2006 Dec;17(6):475-86. Review. Erratum in: Cytokine Growth Factor Rev. 2007 Jun-Aug;18(3-4):345. Nasser, Al-Shanti [corrected to Al-Shanti, Nasser].

PMID:
17118696
7.

Cytokines and cancer anorexia cachexia syndrome.

Bennani-Baiti N, Davis MP.

Am J Hosp Palliat Care. 2008 Oct-Nov;25(5):407-11. doi: 10.1177/1049909108315518. Review.

PMID:
18403577
8.

Cancer cachexia.

Tisdale MJ.

Curr Opin Gastroenterol. 2010 Mar;26(2):146-51. doi: 10.1097/MOG.0b013e3283347e77. Review.

PMID:
19918173
9.

Catabolic mediators of cancer cachexia.

Tisdale MJ.

Curr Opin Support Palliat Care. 2008 Dec;2(4):256-61. Review.

PMID:
19069310
10.

Pathogenesis of muscle wasting in cancer cachexia: targeted anabolic and anticatabolic therapies.

Burckart K, Beca S, Urban RJ, Sheffield-Moore M.

Curr Opin Clin Nutr Metab Care. 2010 Jul;13(4):410-6. doi: 10.1097/MCO.0b013e328339fdd2. Review.

11.

Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia.

Argilés JM, Busquets S, Felipe A, López-Soriano FJ.

Int J Biochem Cell Biol. 2005 May;37(5):1084-104. Review.

PMID:
15743680
12.

The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting.

Tisdale MJ.

J Support Oncol. 2005 May-Jun;3(3):209-17. Review.

PMID:
15915823
13.
14.

Myostatin/activin pathway antagonism: molecular basis and therapeutic potential.

Han HQ, Zhou X, Mitch WE, Goldberg AL.

Int J Biochem Cell Biol. 2013 Oct;45(10):2333-47. doi: 10.1016/j.biocel.2013.05.019. Review.

PMID:
23721881
15.

Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia.

Yoshida T, Tabony AM, Galvez S, Mitch WE, Higashi Y, Sukhanov S, Delafontaine P.

Int J Biochem Cell Biol. 2013 Oct;45(10):2322-32. doi: 10.1016/j.biocel.2013.05.035. Review.

16.

Mechanisms of cancer cachexia.

Tisdale MJ.

Physiol Rev. 2009 Apr;89(2):381-410. doi: 10.1152/physrev.00016.2008. Review.

17.

Cachexia, survival and the acute phase response.

Stephens NA, Skipworth RJ, Fearon KC.

Curr Opin Support Palliat Care. 2008 Dec;2(4):267-74. doi: 10.1097/SPC.0b013e3283186be2. Review.

PMID:
19060563
18.

[Systemic and local mechanisms leading to cachexia in cancer].

Grabiec K, Burchert M, Milewska M, Błaszczyk M, Grzelkowska-Kowalczyk K.

Postepy Hig Med Dosw (Online). 2013 Dec 31;67:1397-409. doi: 10.5604/17322693.1085135. Review. Polish.

19.

Cancer cachexia: mediators, signaling, and metabolic pathways.

Fearon KC, Glass DJ, Guttridge DC.

Cell Metab. 2012 Aug 8;16(2):153-66. doi: 10.1016/j.cmet.2012.06.011. Review.

20.

Pathogenesis of cancer cachexia.

Tisdale MJ.

J Support Oncol. 2003 Sep-Oct;1(3):159-68. Review.

PMID:
15334872
Items per page

Supplemental Content

Support Center